Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating polycystic ovary syndrome (PCOS)

A polycystic ovary and composition technology, applied in the field of polycystic ovary syndrome treatment, can solve problems such as ovarian damage, pelvic adhesions, and fetal harm

Inactive Publication Date: 2013-04-17
上海泰坤堂中医医院有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs not only cannot effectively treat all PCOS, but also have defects such as low pregnancy rate and high miscarriage rate
Surgical puncture techniques are also used in the treatment of PCOS, which may cause damage to the ovaries, or cause pelvic adhesions and potential harm to the fetus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating polycystic ovary syndrome (PCOS)
  • Pharmaceutical composition for treating polycystic ovary syndrome (PCOS)
  • Pharmaceutical composition for treating polycystic ovary syndrome (PCOS)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] The preparation of embodiment 1 decoction

[0054] Take 15g Anemarrhena, 12 Fritillaria, 24g Zhishouwu, 12g Ophiopogon japonicus, 12g Tortoise shell, 0.6g hippocampus, 9g Angelica sinensis, 15g Saponaria thorn, and 15g Shichangpu, rinse with water, soak in the container for more than 2 hours, and then use The traditional decocting process of decocting first and then decocting, decocting at normal pressure for 20 minutes to filter out the medicinal liquid.

Embodiment 2

[0055] The preparation of embodiment 2 ointment

[0056] Take 150g Anemarrhena, 120g Fritillaria, 260g Zhishouwu, 120g Ophiopogon japonicus, 120g Tortoise shell, 6g hippocampus, 90g Angelica sinensis, 150g Saponaria thorn, and 150g Shichangpu, rinse with water, soak in the container for more than 2 hours, and then use the first The traditional decoction process of decocting and decocting. After decocting under normal pressure, the liquid medicine is filtered out and the liquid medicine is concentrated under reduced pressure. During the process of concentrating the liquid medicine, sugars and necessary auxiliary materials such as rock sugar, maltose and rice wine are added, and stirred Receive ointment.

Embodiment 3

[0057] Embodiment 3 clinical observation

[0058] Patients with kidney yin deficiency and phlegm and blood stasis are included according to the following criteria:

[0059] A) Diagnostic criteria of Western medicine: 1) Menstrual cramps for more than 2 years are still anovulatory menstruation (BBT monophasic), oligomenorrhea or amenorrhea; 2) Blood androgen rise: on the third day of uterine bleeding, blood testosterone (T) rises High or testosterone / estradiol logarithmic ratio (Log(T / E 2 ))>0.97; 17α-hydroxyprogesterone (17α-OHP) and androstenedione can be combined to increase; 3) B-ultrasound examination found that the ovarian volume increased (≥6ml), and the number of follicles with a diameter of 2-9mm on a plane in the cortex >10.

[0060] B) TCM syndrome classification standard: In addition to less menstrual period or amenorrhea, infertility, accompanied by dry mouth, upset, internal heat, leukorrhea, constipation, etc., dark red tongue, less coating, thready pulse.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating polycystic ovary syndrome (PCOS). The pharmaceutical composition consists of a traditional Chinese medicine composition and chemical drugs, wherein the traditional Chinese medicine composition comprises the medicinal materials such as anemarrhena, fritillary bulb, tortoise plastron, fleece-flower root, lilyturf root, hippocampus andthe like; and the chemical drugs comprise one or more compound molecules of dexamethasone, spirolactone, ethinyloestradiol, estradiol valerate, conjugated estrogen and pharmaceutically acceptable salt. The pharmaceutical composition has the advantages of reducing the level of androgens and androgen receptors of patients suffering from PCOS, improving the level of sex hormone-binding globulin (SHBG), lowering the level of free testosterone (F-TESTO), further raising the level of in-vivo estrogens, improving growth and development of follicles and increasing ovulation rate and pregnancy rate ofthe patients.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition composed of a variety of Chinese medicinal materials in accordance with the compatibility of monarch, minister, adjuvant, and shi, and chemical drugs with compound molecules as active ingredients. For the treatment of polycystic ovary syndrome. Background technique [0002] Polycystic ovary syndrome (Polycystic Ovary Syndrome, PCOS) was proposed by Stein and Leventhal in 1935. A type of disease manifested. This disease is a common endocrine disease in women and mostly causes reproductive disorders, and its incidence rate accounts for 5%-10% of women of childbearing age. Studies in recent years have widely recognized that women with PCOS have different degrees of insulin resistance, and insulin resistance accompanied by hyperinsulinemia can cause many clinical symptoms, such as: excessive androgen levels, reproductive disorders, metabolic disor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/8968A61K36/9066A61K45/00A61P15/08A61K31/565A61K31/567A61K31/573A61K31/585A61K33/26A61K35/56A61K35/64A61K35/586A61K35/60
Inventor 俞谨潘芳武大圣
Owner 上海泰坤堂中医医院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com